EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre‐transplant minimal residual disease on outcomes in high‐risk acute lymphoblastic leukemia patients in complete remission

Xiaoyan Zhao, Ziwei Xu, Ziying Li, Xi Zhou, Yu Hu, Huafang Wang iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.6897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Xiaoyan Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Cyclophosphamide, Etoposide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Among high‐risk acute lymphoblastic leukemia (ALL) patients undergoing allogeneic hematopoietic stem cell transplantation (allo‐HSCT), those with positive minimal residual disease (MRD) are susceptible to poor outcomes. Therefore, it is necessary to determine the most suitable preparatory regimen for these patients.

Methods

Data were analyzed from 141 patients who received allo‐HSCT and were diagnosed with high‐risk ALL. These patients underwent intensified conditioning regimens, including either total marrow and lymphoid irradiation (TMLI)‐etoposide (VP16)‐cyclophosphamide (CY) or busulfan (BU)‐VP16‐CY between October 2016 and November 2022. A total of 141 individuals were in complete remission (CR) before transplantation and, among all patients, 90 individuals exhibited a negative MRD status and 51 patients had a positive MRD status.

Results

In patients who tested negative for MRD, the incidence of relapse within a 2‐year timeframe was 25.0% (24.8%–25.5%), compared with 32.2% (31.2%–33.2%) in MRD‐positive patients; however, this difference was not statistically significant. There were no significant differences in the 2‐year disease‐free survival (DFS) and 2‐year overall survival (OS) rates between the MRD‐negative and MRD‐positive groups (DFS: 67.2% (57.9%–78.1%) vs. 55.5% (42.6%–72.3%); OS: 69.0% (61.9%–88.2%) vs. 66.7% (53.9%–82.5%)). Furthermore, no notable variations were observed in the occurrence of transplant‐related mortality (TRM) and graft‐versus‐host disease (GVHD) across the two groups.

Conclusion

This study reveals the benefits of TMLI‐VP16‐CY and BU‐VP16‐CY conditioning regimens in high‐risk ALL patients with CR and MRD‐positive status. A large‐scale prospective clinical trial is warranted in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaCyclophosphamideEtoposideBusulfanTransplantation ConditioningHematopoietic Stem Cell TransplantationRemission InductionAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleAdultAdolescentYoung AdultChildMiddle AgedRetrospective StudiesTreatment OutcomeChild, PreschoolTransplantation, HomologousPathologic Complete Response

Stichwörter der Autor:innen

acute lymphoblastic leukemiahematopoietic stem cell transplantationintensified conditioning regimenminimal residual disease

Substanzen

CyclophosphamideEtoposideBusulfan

Autor:innen und Institutionen

  • Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Huafang Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhao, X., Xu, Z., Li, Z., Zhou, X., Hu, Y., & Wang, H. (2024). Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre‐transplant minimal residual disease on outcomes in high‐risk acute lymphoblastic leukemia patients in complete remission. Cancer Medicine. https://doi.org/10.1002/cam4.6897

Vancouver

Zhao X, Xu Z, Li Z, Zhou X, Hu Y, Wang H. Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre‐transplant minimal residual disease on outcomes in high‐risk acute lymphoblastic leukemia patients in complete remission. Cancer Medicine. 2024. doi:10.1002/cam4.6897

BibTeX
@article{Zhao2024,
  author = {Zhao, Xiaoyan and Xu, Ziwei and Li, Ziying and Zhou, Xi and Hu, Yu and Wang, Huafang},
  title = {Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre‐transplant minimal residual disease on outcomes in high‐risk acute lymphoblastic leukemia patients in complete remission},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6897}
}
Kostenlos starten →